RT Journal Article
SR Electronic
T1 Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4837
DO 10.1183/13993003.congress-2016.PA4837
VO 48
IS suppl 60
A1 Chou-Han Lin
A1 Chao-Chi Ho
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA4837.abstract
AB Purpose: Whether different or equal efficacy of tyrosine kinase inhibitor (TKI) according to epidermal growth factor receptor (EGFR) is still debated. We undertook a study to evaluate the clinical efficacy of gefitinib as first-line treatment in patients with lung adenocarcinoma carrying exon 19 deletion or L858R point mutation.Materials and methods: We retrospectively reviewed all newly diagnosed lung adenocarcinoma patients who received gefitinib for advanced diseases. Chemotherapy-naïve patients who did not participate in clinical trials of first-line treatment were enrolled. Their charts and images were reviewed.Results: Between June. 2013 and December 2014, one hundred and fifty-one patients met the criteria for inclusion in the study. The exon 19 deletion was found in 67/151 patients and the L858R point mutation in 84/151. The median progression-free survival (PFS) in the overall patient population was 9.9 months. The median PFS was 9.6 months in patients with exon 19 deletion and 10.2 months in those with L858R point mutation (p=0.69). The median PFS was 10.8 months in patients with postoperative recurrence and 9.6 months in those with stage IIIB/IV (p=0.014). Multivariable analysis revealed that only postoperative recurrence remains an independent prognostic factor for better PFS (hazard ratio,0.43; 95% CI, 0.21-0.85; p=0.016).Conclusions: There is no difference in clinical efficacy of gefitinib in lung adenocarcinoma patients harboring either exon 19 deletion or L858R point mutation. Patients with postoperative recurrence disease have a favorable prognosis and should be separated from patients with stage IIIB/IV in future clinical trials.